A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis

Sponsor
Celltrion
Study ID
NCT04171414
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Clinical trial to evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis

Key Dates

Start date
Sep 9, 2019
Status verified
Oct 2021
Primary completion
Nov 4, 2019
Completion
Apr 24, 2020

Study Design

Enrollment
62 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: "CT-P17 SC AI (adalimumab)"
    CT-P17 Subcutaneous(SC) Autoinjector(AI) (adalimumab)

Primary Outcome Measure

The Usability as Assessed by Patients Rating Using PRE- and POST-Self-Injection Assessment Questionnaire (SIAQ) at Week 4 [ Time Frame: Week 4 ]

Related Studies